000			01895 a2200517 4500
005			20250513170644.0
264		0	_c19990430
008			199904s 0 0 eng d
022			_a0066-4219
024	7		_a10.1146/annurev.med.50.1.129 _2doi
040			_aNLM _beng _cNLM
100	1		_aWarkentin, T E
245	0	0	_aHeparin-induced thrombocytopenia: a ten-year retrospective. _h[electronic resource]
260			_bAnnual review of medicine _c1999
300			_a129-47 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAntibodies _ximmunology
650	0	4	_aAnticoagulants _xadverse effects
650	0	4	_aAntithrombin III _xtherapeutic use
650	0	4	_aChondroitin Sulfates _xtherapeutic use
650	0	4	_aDermatan Sulfate _xtherapeutic use
650	0	4	_aDrug Combinations
650	0	4	_aFibrinolytic Agents _xtherapeutic use
650	0	4	_aGangrene _xchemically induced
650	0	4	_aHeparin _xadverse effects
650	0	4	_aHeparinoids _xtherapeutic use
650	0	4	_aHeparitin Sulfate _xtherapeutic use
650	0	4	_aHirudin Therapy
650	0	4	_aHirudins _xanalogs & derivatives
650	0	4	_aHumans
650	0	4	_aImmunoglobulin G _ximmunology
650	0	4	_aLeg _xblood supply
650	0	4	_aPlatelet Activation _ximmunology
650	0	4	_aPlatelet Factor 4 _ximmunology
650	0	4	_aProtein C Deficiency _xchemically induced
650	0	4	_aReceptors, IgG _ximmunology
650	0	4	_aRecombinant Proteins _xtherapeutic use
650	0	4	_aRetrospective Studies
650	0	4	_aSyndrome
650	0	4	_aThrombin _xbiosynthesis
650	0	4	_aThrombocytopenia _xchemically induced
650	0	4	_aVenous Thrombosis _xchemically induced
650	0	4	_aWarfarin _xadverse effects
773	0		_tAnnual review of medicine _gvol. 50 _gp. 129-47
856	4	0	_uhttps://doi.org/10.1146/annurev.med.50.1.129 _zAvailable from publisher's website
999			_c10033243 _d10033243